Literature DB >> 14569064

Potent antioxidant properties of 4-hydroxyl-propranolol.

I Tong Mak1, William B Weglicki.   

Abstract

The antioxidant properties of 4-HO-propranolol (4HOP), a major metabolite of propranolol, were studied and compared with that of propranolol and vitamin E (Trolox). When isolated hepatic microsomal membranes were peroxidized by an iron-catalyzed.OH-generating system [dihydroxyfumarate +Fe (III)], 4HOP potently and concentration-dependently inhibited lipid peroxidation; the IC50 value was 1.1 microM, whereas those for Trolox and propranolol were 4.3 and 168 microM, respectively. When isolated human low-density lipoprotein (LDL) was oxidized by 7.5 microM Cu(II) for 9 h, 4HOP at 3 microM delayed the lag phase significantly by 108 min, which was comparable with that of probucol (98-min delay) but was far greater than that provided by propranolol (6 min) or Trolox (47 min). At 1 microM 4HOP, the delay was 45 min. When confluent cultured bovine aortic endothelial cells were exposed to the Fe-catalyzed oxy-radical system, acute loss of glutathione occurred (55% decrease in 50 min). Pretreatment of the cells with 0.067 to 6.7 microM 4HOP for 30 min provided increasing degrees of protection against the glutathione loss; the EC50 value was 1.2 microM, whereas those for Trolox and propranolol were 7.9 and 49 microM, respectively. The loss of cell survival due to the radical stress was also effectively preserved by 4HOP. In separate experiments, when the endothelial glutathione was oxidatively depleted by a peroxynitrite-generating system (3-morpholinosydnonimine), 4HOP also provided potent protective activities. In conclusion, 4HOP is 4- to 8-fold more potent than vitamin E and >100-fold more active than propranolol as a "chain-breaking" antiperoxidatant against membrane and LDL oxidation and can provide superior endothelial cytoprotective efficacy against oxygen- or nitrogen-derived oxidant-mediated cell injury. Being a major metabolite in human and with its plasma level approaching that of propranolol, 4-HO-propranolol may contribute, in part, to the cardiovascular therapeutic benefits of propranolol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569064     DOI: 10.1124/jpet.103.058032

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Nitrones as therapeutics.

Authors:  Robert A Floyd; Richard D Kopke; Chul-Hee Choi; Steven B Foster; Sabrina Doblas; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2008-08-29       Impact factor: 7.376

Review 2.  The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases.

Authors:  A Rietz; Jp Spiers
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Ocular Safety of Intravitreal Propranolol and Its Efficacy in Attenuation of Choroidal Neovascularization.

Authors:  Ramin Nourinia; Mozhgan Rezaei Kanavi; Amir Kaharkaboudi; Seyed Iman Taghavi; Seyed Javid Aldavood; Soesiawati R Darjatmoko; Shoujian Wang; Zafer Gurel; Jeremy A Lavine; Sare Safi; Hamid Ahmadieh; Narsis Daftarian; Nader Sheibani
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

4.  Increased poly(ADP-ribosyl)ation in skeletal muscle tissue of pediatric patients with severe burn injury: prevention by propranolol treatment.

Authors:  Gábor Oláh; Celeste C Finnerty; Elena Sbrana; Itoro Elijah; Domokos Gerö; David N Herndon; Csaba Szabó
Journal:  Shock       Date:  2011-07       Impact factor: 3.454

5.  Angiotensin II promotes iron accumulation and depresses PGI₂ and NO synthesis in endothelial cells: effects of losartan and propranolol analogs.

Authors:  I Tong Mak; Kenneth M Landgraf; Joanna J Chmielinska; William B Weglicki
Journal:  Can J Physiol Pharmacol       Date:  2012-10-15       Impact factor: 2.273

6.  Propranolol reduces systemic oxidative stress and endotoxemia in cirrhotic patients with esophageal varices.

Authors:  Dimitra Taprantzi; Dimitrios Zisimopoulos; Konstantinos C Thomopoulos; Iris Spiliopoulou; Christos D Georgiou; Georgios Tsiaoussis; Christos Triantos; Charalambos A Gogos; Chrisoula Labropoulou-Karatza; Stelios F Assimakopoulos
Journal:  Ann Gastroenterol       Date:  2017-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.